Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.81
-0.09 (-1.30%)
At close: May 29, 2026, 4:00 PM EDT
6.91
+0.10 (1.44%)
After-hours: May 29, 2026, 5:10 PM EDT
Profound Medical Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Profound Medical stock has a consensus rating of "Strong Buy" and an average price target of $11.14. The average 1-year stock price forecast is 63.58% higher than the current stock price, while the lowest is $10 (+46.84%) and the highest is $12 (+76.21%).
Price Target: $11.14 (+63.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Profound Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Buy Reiterates $12 | Buy | Reiterates | $12 | +76.21% | May 18, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $12 → $10 | Buy | Reiterates | $12 → $10 | +46.84% | May 8, 2026 |
Financial Forecast
Revenue This Year
30.97M
from 16.10M
Increased by 92.40%
Revenue Next Year
50.83M
from 30.97M
Increased by 64.10%
EPS This Year
-0.90
from -1.41
EPS Next Year
-0.68
from -0.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 33.2M | 55.4M | ||||||
| Avg | 31.0M | 50.8M | ||||||
| Low | 29.4M | 46.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 106.1% | 79.0% | ||||||
| Avg | 92.4% | 64.1% | ||||||
| Low | 82.6% | 50.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.83 | -0.58 | ||||||
| Avg | -0.90 | -0.68 | ||||||
| Low | -0.99 | -0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.